Arch Craniofac Surg.  2017 Mar;18(1):54-58. 10.7181/acfs.2017.18.1.54.

Treatment of Tongue Lymphangioma with Intralesional Combination Injection of Steroid, Bleomycin and Bevacizumab

• Hwang J
• Lee YK
• Burm JS

• KMID: 2375224
• DOI: http://doi.org/10.7181/acfs.2017.18.1.54

Abstract

Lymphangioma is a congenital malformed lymphatic tumor that rarely involves the tongue. In our clinic, a 10-year-old female presented with lymphangioma circumscriptum involving the right two-thirds of the tongue. We administered an intralesional combination injection of triamcinolone, bleomycin, and bevacizumab as a treatment. Almost complete remission after combination therapy was achieved without complications such as edema, swallowing difficulties or recurrence. Bevacizumab, an inhibitor of vascular endothelial growth factor, was effective for the treatment of lymphangioma of the tongue in this case. No recurrence was noted at the 1-year follow up.

Keyword

Lymphangioma; Tongue; Steroid; Bleomycin; Bevacizumab

MeSH Terms

Bevacizumab*
Bleomycin*
Child
Deglutition
Edema
Female
Follow-Up Studies
Humans
Lymphangioma*
Recurrence
Tongue*
Triamcinolone
Vascular Endothelial Growth Factor A
Bevacizumab
Bleomycin
Triamcinolone
Vascular Endothelial Growth Factor A